喘可治注射液联合高流量呼吸湿化治疗仪治疗慢性阻塞性肺疾病急性加重期合并呼吸衰竭的临床效果

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (0 KB) HTML (46 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Chuankezhi injection combined with high flow humidified oxygen delivery devices(AIRVO2)in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD)complicated with respiratory failure and its influence on inflammatory mediators and cellular immune status.Methods A total of 122 AECOPD patients with respiratory failure admitted to the Department of Pulmonary and Critical Care Medicine of Dongguan Hospital of Traditional Chinese Medicine from September 2019 to November 2020 were selected and divided into the treatment group and the control group according to random number table method,61 cases in each group,1 case left out in each group,and 60 cases completed in each group.The control group was given AIRVO2,anti infection,expectorant and bronchial relaxation according to the guidelines.The treatment group was given Chuankezhi Injection on the basis of the control group.And the course of treatment was 14 days in each group.The traditional Chinese medicine syndrome score,the total white blood cell(WBC)count,C-reactive protein(CRP),arterial blood pH value,arterial partial pressure of oxy-gen(PaO2),arterial partial pressure of carbon dioxide(PaCO2)and peripheral blood interleukin-1β (IL-1β),analysis of interleukin-8 (IL-8)and T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)were observed before and after treatment between the two groups.Results There were no significant difference in the traditional Chinese medicine syndrome score,the levels of WBC,CRP,pH value,PaO2,PaCO2,IL-1β,IL-8 and T lymphocyte subsets before treatment between the two group (P＞0.05).After treatment,the levels of WBC,CRP,PaCO2,IL-1β,IL-8 and CD8+in the two groups were lower than those before treatment,and the differences were statistically significant(P＜0.05).After treatment,the levels of pH value,PaO2,CD3+,CD4+,CD4+/CD8+in the two groups were higher than those before treatment,and the differences were statistically significant(P＜0.05).The levels of WBC,CRP,PaCO2,IL-1β,IL-8 and CD8+in the treatment group after treatment were significantly lower than those in the control group,and the differences were statistically significant(P＜0.05).After treatment,the levels of pH value,PaO2,CD3+,CD4+,CD4+/CD8+of the treatment group were higher than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion Chuankezhi injection combined with AIRVO2can significantly improve the clinical effect of AECOPD with respiratory failure,and improve the inflammatory response and cellular immune status of patients.

Key words： Chuankezhi injection High flow humidified oxygen delivery devices Chronic obstructive pulmonary disease Respiratory failure Cellular immunity

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIAN Xu-sheng
	LI Bi-fang
	TAO Hai-lan
	ZHU Bi-yuan
	LIAN Le-shen
	WANG Ying-kang
	GUO Wei-xing

Cite this article:

QIAN Xu-sheng,LI Bi-fang,TAO Hai-lan, et al. Clinical effect of Chuankezhi injection combined with high flow humidified oxygen delivery device in the treatment of acute exacerbation of chronic obstructive pulmonary disease complicated with respiratory failure[J]. 中国当代医药, 2021, 28(31): 168-172.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I31/168

[1]	Zhong NS，Wang C，Ran PX.Prevalence of chronic obstructive pulmonary disease in China[J].Am J Respir Crit Care Med，2007，176（8）：753-760.
[2]	Murray CJL，Lopez AD.Alternative projections of mortality and disability by cause 1990-2020：Global Burden of Disease Study[J].Lancet，1997，349（9064）：1498-1504.
[3]	郭子强，王心旺.慢性阻塞性肺疾病住院患者的疾病经济负担研究[J].中国卫生统计，2010，4（23）：345-347.
[4]	陈诗琪，杨欣宇，唐潇旖，等.喘可治注射液治疗慢性阻塞性肺疾病急性加重期的系统评价[J].中国中药杂志，2017，42（14）：2789-2795.
[5]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中国医学前沿杂志（电子版），2014，6（2）：67-80.
[6]	蔡柏蔷，李龙芸.协和呼吸病学[M].2版.北京：中国协和医科大学出版社，2010：59.
[7]	田德禄.中医内科学[M].北京：人民卫生出版社，2002：102.
[8]	郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：54-58.
[9]	俞正霞，李俊，朱旭婷.喘可治注射液治疗COPD稳定期的临床疗效观察[J].临床肺科杂志，2010，15（9）：1280-1281.
[10]	程玉武.COPD患者血清 IL-6、IL-8、TNF-α 水平的检测及意义[J].山东医药，2010，50（27）：47-48.
[11]	黄秘.哮喘及COPD患者FeNO水平与血清IL-1β、IL-9水平相关性研究[D].荆州：长江大学，2019.
[12]	骆彩虹.基于IL-1β/COX-2信号通路探讨苗药吉祥草抑制COPD气道黏液高分泌的分子机制研究[D].贵阳：贵阳中医学院，2018.
[13]	闫芳，焦克岗，郗慧.血清细胞因子及急性期反应蛋白与COPD患者抑郁情绪的相关分析[J].临床肺科杂志，2011，16（10）：1514-1516.
[14]	杨文漪，王金湖，曹季军，等.COPD患者血清IL-6、CRP、血浆NT-proBNP与肺功能的相关性及其对病情的预测价值[J].检验医学与临床，2020，17（23）：3459-3462.
[15]	梁彩妮，廖永城，邱宇，等.RDW在COPD患者并发不同程度肺动脉高压的表达及相关性[J].分子诊断与治疗杂志，2020，12（11）：1501-1504，1509.
[16]	余雪姣，陈秀花，单旦萍.慢性阻塞性肺疾患者病程中免疫功能状况的临床观察[J].浙江临床医学，2018，20（4）：737-738.
[17]	钱俊峰，王洪源，徐芳，等.喘可治注射液联合舒利迭对老年COPD急性加重期患者T淋巴细胞亚群、炎症介质和凝血功能的影响[J].中国老年学杂志，2018，38（20）：4930-4932.
[18]	程亮星.巴戟天寡糖对大鼠子宫缺血再灌注损伤的抗炎作用[J].中医研究，2018，31（6）：68-70.
[19]	徐超斗，张永祥，杨明，等.巴戟天寡糖的促免疫活性作用[J].解放军药学学报，2003，19（6）：466-468.
[20]	王瀚，马紫童，唐秀凤，等.基于网络药理学探寻淫羊藿治疗哮喘的关键靶标及作用机制[J].世界中医药，2021，16（5）：742-750.
[21]	刘天明.淫羊藿苷对小鼠免疫细胞功能的调节作用[D].锦州：锦州医科大学，2016.
[22]	梁锡铭，陈雪丽，王丹，等.AIRVO2型呼吸湿化治疗仪治疗慢性阻塞性肺疾病合并Ⅱ型呼吸衰竭的临床效果研究[J].中国医学装备，2017，14（11）：81-84.
[23]	远青钊，罗琴，王在义.经鼻高流量加温湿化吸氧治疗在慢性阻塞性肺疾病合并呼吸衰竭患者中应用的疗效观察[J].新疆医科大学学报，2018，41（5）：556-559，564.
[24]	叶曜衢，曾燕转，苏月南，等.AIRVO2无创呼吸湿化治疗仪与Trilogy100无创呼吸机在治疗慢性阻塞性肺疾病合并呼吸衰竭患者中的疗效对比研究[J].岭南急诊医学杂志，2016，21（6）：615-616.